Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease
A. J. B. Kreutzberger, A. Sanyal, R. Ojha, J. Pyle, O. Vapalahti, G. Balistreri, T. Kirchhausen
This study finds that combining apilimod and camostat mesylate or nafamostat mesylate significantly enhances inhibition of SARS-CoV-2 infection in vitro.
bioRxiv · Jun 1, 2021Microbiology